<table className="table"><caption><p>Monitoring of Gender-Affirming Hormonal Therapy</p></caption><thead><tr><th colSpan="1" rowSpan="1"><p>Monitoring</p></th><th colSpan="1" rowSpan="1"><p>Transgender Men</p></th><th colSpan="1" rowSpan="1"><p>Transgender Women</p></th></tr></thead><tbody><tr className="group_1-1 row-odd"><td colSpan="1" rowSpan="1"><p>Frequency of follow-up<sup>a</sup></p></td><td colSpan="1" rowSpan="1"><p>Every 3 months (or with dosage changes) during the first year of treatment</p><p>Every 6-12 months thereafter</p></td><td colSpan="1" rowSpan="1"><p>Every 3 months (or with dosage changes) during the first year of treatment</p><p>Every 6-12 months thereafter</p></td></tr><tr className="group_1-2 row-even"><td colSpan="1" rowSpan="1"><p>Clinical evaluation at each visit</p></td><td colSpan="1" rowSpan="1"><p>Blood pressure, weight, pulse rate</p><p>Physical examination, including cardiopulmonary and skin examination</p><p>Monitor for appropriate signs of virilization</p><p>Monitor for adverse reactions, excess weight gain, acne, uterine breakthrough bleeding, cardiovascular risk, and for psychiatric symptoms in patients at high risk</p></td><td colSpan="1" rowSpan="1"><p>Blood pressure, weight, pulse rate</p><p>Physical examination, including cardiopulmonary examination</p><p>Monitor for appropriate signs of feminization</p><p>Monitor for adverse reactions; assess for signs of cardiovascular risk and venous thromboembolism</p></td></tr><tr className="group_1-3 row-odd"><td colSpan="1" rowSpan="1"><p>Laboratory evaluation</p></td><td colSpan="1" rowSpan="1"><p>Testosterone: Measure every 3 months (or with dosage changes) for the first year with titration to physiologic male range (400-700 ng/dL [13.9-24.3 nmol/L]), then every 6-12 months thereafter</p><p>Estradiol: Measure every 3 months (or with dosage changes) for the first year with titration to goal (&lt;50 pg/mL [183.5 pmol/L] and cessation of menstrual bleeding), then every 6-12 months thereafter</p><p>Hematocrit or hemoglobin: Measure before therapy initiation, every 3 months in the first year, then every 6-12 months thereafter</p><p>Lipids: Monitor periodically</p><p>Fasting plasma glucose and hemoglobin A<sub>1c</sub>: Monitor in patients with personal or family history of diabetes mellitus</p></td><td colSpan="1" rowSpan="1"><p>Testosterone: Measure every 3 months (or with dosage changes) for the first year with titration to goal (&lt;50 ng/dL [1.7 nmol/L]), then every 6-12 months thereafter</p><p>Estradiol: Measure every 3 months (or with dosage changes) for the first year with titration to physiologic female range (100-200 pg/mL [367-734 nmol/L]), then every 6-12 months thereafter</p><p>Patients taking spironolactone: monitor serum electrolytes (notably potassium) every 3 months (or with dosage changes) during the first year of therapy, then every 6-12 months thereafter</p><p>Lipids and prolactin: Perform periodic and individualized monitoring</p><p>Fasting plasma glucose and hemoglobin A<sub>1c</sub>: Monitor in patients with a personal or family history of diabetes</p></td></tr><tr className="group_1-4 row-even"><td colSpan="1" rowSpan="1"><p>Screening</p></td><td colSpan="1" rowSpan="1"><p>If cervical tissue is present, screen for cervical cancer as in cisgender persons</p><p>If breast tissue is present, screen for breast cancer with mammography as in cisgender persons</p><p>Baseline bone mineral density testing in patients with risk factors for osteoporosis and in patients who stop hormone therapy after gonadectomy</p></td><td colSpan="1" rowSpan="1"><p>Routine cancer screening (colon, prostate) is recommended as in cisgender persons</p><p>Baseline bone mineral density testing in patients with risk factors for osteoporosis, in patients who stop hormone therapy after gonadectomy, or at age 60 years in patients with low risk</p></td></tr></tbody></table>